Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa N Abaid

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Oncology|June 14, 2014
The incidence of genitourinary and gastrointestinal complications in open and endoscopic gynecologic cancer surgeryChristopher R Rettenmaier, Nicholas B Rettenmaier, Lisa N Abaid, et al.
JAMA Oncology|May 25, 2023
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical TrialRobert W Holloway, Alberto A Mendivil, James E Kendrick, et al.
Vaccines|November 26, 2025
Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian CancerLisa N Abaid, Bradley R Corr, Ramez N Eskander, et al.
Gynecologic Oncology|November 13, 2007
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovaryKathleen N Moore, Katherine M Moxley, Amanda Nickles Fader, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Oncology|June 14, 2014
The incidence of genitourinary and gastrointestinal complications in open and endoscopic gynecologic cancer surgeryChristopher R Rettenmaier, Nicholas B Rettenmaier, Lisa N Abaid, et al.
JAMA Oncology|May 25, 2023
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical TrialRobert W Holloway, Alberto A Mendivil, James E Kendrick, et al.
Vaccines|November 26, 2025
Double-Blind Randomized Phase 2 Trial Testing Personal Cancer Vaccines in Patients with Advanced Ovarian CancerLisa N Abaid, Bradley R Corr, Ramez N Eskander, et al.
Gynecologic Oncology|November 13, 2007
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovaryKathleen N Moore, Katherine M Moxley, Amanda Nickles Fader, et al.
Pageof 5